Developer docs
API playgroundTry for free, no card

Search company profiles

Eppin Pharma

Full company profile

uuid0004jvg

Namestring
Eppin Pharma
Company typeenum
Private
Founded yearint
2001
Short descriptiontext

Eppin Pharma is a private Durham, North Carolina-based pharmaceutical company developing a single non-hormonal oral male contraceptive pill currently in early proof-of-concept clinical trials, targeting men of reproductive age.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersDurham, United States
HQ citystring
Durham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
male contraceptive drug, non-hormonal contraception, reproductive health pharmaceutical, clinical stage biopharmaceutical, contraceptive clinical trials
Industry1 code
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Reproductive Health Pharmaceuticals (Male Contraceptives)
Social media profiles2 records
Revenue model1 record
1Pharmaceutical product revenue (future)
TypeOne Time License
Description

Pre-revenue company developing a non-hormonal male contraceptive pill. Revenue model will be through pharmaceutical product sales following regulatory approval and commercialization.

biospace.com
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Eppin Pharma is developing a novel non-hormonal, orally administered male contraceptive pill intended to provide reversible male birth control without hormonal intervention. The product is in early clinical development, with current activities focused on proof-of-concept studies for safety and feasibility to support future larger efficacy trials and regulatory approval.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Non-hormonal Male Contraceptive Pill
CategoryMale Contraceptive Pharmaceutical (clinical stage)
Description

A novel non-hormonal male contraceptive pill designed to provide reversible male birth control without hormonal intervention. The product is intended for men of reproductive age seeking non-hormonal contraceptive options and is currently in clinical trials to establish proof-of-concept for safety and feasibility before larger efficacy studies for regulatory approval.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Peers10 records
TypeDirect peer
Description

Contraline is developing a non-hormonal, long-acting male contraceptive (ADAM hydrogel/Vasalgel). It is the most direct competitor to Eppin Pharma, sharing the non-hormonal mechanism and male contraceptive target, with a different delivery format.

TypeDirect peer
Description

YourChoice Therapeutics is developing a non-hormonal contraceptive for men, working on a reversible, on-demand male birth control method. It competes for the same end users and unmet need that Eppin Pharma is targeting.

TypeBroad incumbent
Description

Evofem Biosciences develops and commercializes products in women's sexual and reproductive health, including hormone-free contraceptives. Its hormone-free positioning mirrors Eppin Pharma's non-hormonal differentiation strategy in the reproductive health space.

TypeBroad incumbent
Description

Cosette Pharmaceuticals is a specialty pharmaceutical company with a portfolio including women's health and contraceptive products. As a broader reproductive health pharma player, it represents a comparable business model and potential commercialization partner.

TypeBroad incumbent
Description

Bayer's pharmaceutical division has historically been a major player in contraception (e.g., Yaz, Mirena). As a global incumbent in hormonal and device-based contraception, it represents both a potential acquirer and a competitor for the male contraceptive market Eppin Pharma is targeting.

TypeEmerging player
Description

The Population Council is a nonprofit research organization that has historically advanced reproductive health technologies including male contraception. While not a direct commercial peer, it operates in the same reproductive health R&D space and overlaps in male contraceptive research.

TypeEmerging player
Description

Dare Bioscience is a clinical-stage biopharmaceutical company focused on women's reproductive health. While its primary focus is female contraception, it competes for the same overall reproductive health market and investor capital as Eppin Pharma.

TypeBroad incumbent
Description

Merck has previously invested in male contraceptive research programs and remains a global pharmaceutical incumbent. Its historical interest in male contraception makes it a relevant comparable for the broader R&D direction Eppin Pharma is pursuing.

TypeDirect peer
Description

NEXT Life Sciences (formerly known as Plan A) is developing a non-hormonal, reversible male contraceptive. It pursues the same target market as Eppin Pharma — men seeking reversible contraception without hormonal intervention — making it a close direct peer.

TypeBroad incumbent
Description

Organon is a global women's health company spun out of Merck that markets multiple contraceptive products. As a broad incumbent in the reproductive health pharmaceutical space, it represents the type of large commercial player Eppin Pharma would ultimately partner with or compete against.

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Eppin Pharma

Reproductive Health Pharmaceuticals (Male Contraceptives)eppinpharmainc.com

Eppin Pharma is a private Durham, North Carolina-based pharmaceutical company developing a single non-hormonal oral male contraceptive pill currently in early proof-of-concept clinical trials, targeting men of reproductive age.

Eppin Pharma firmographics

Firmographics
Name
Eppin Pharma
Website
https://eppinpharmainc.com
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
1–10 employees
Short description
Eppin Pharma is a private Durham, North Carolina-based pharmaceutical company developing a single non-hormonal oral male contraceptive pill currently in early proof-of-concept clinical trials, targeting men of reproductive age.
Ownership category
akta.pro rank

Eppin Pharma industry classification

Industry
Product category
Reproductive Health Pharmaceuticals (Male Contraceptives)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Male contraceptive drug
  • Non-hormonal contraception
  • Reproductive health pharmaceutical
  • Clinical stage biopharmaceutical
  • Contraceptive clinical trials

Where Eppin Pharma is headquartered

Location

Headquarters

HQ city
Durham
HQ country
United States
HQ region
North America

Markets served

Eppin Pharma business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Pharmaceutical product revenue (future): Pre-revenue company developing a non-hormonal male contraceptive pill. Revenue model will be through pharmaceutical product sales following regulatory approval and commercialization.

Eppin Pharma product offering

Product offering

Core offering

Eppin Pharma is developing a novel non-hormonal, orally administered male contraceptive pill intended to provide reversible male birth control without hormonal intervention. The product is in early clinical development, with current activities focused on proof-of-concept studies for safety and feasibility to support future larger efficacy trials and regulatory approval.

Differentiator

Problem solved

Functional benefit

Products and services

  • Non-hormonal Male Contraceptive Pill A novel non-hormonal male contraceptive pill designed to provide reversible male birth control without hormonal intervention. The product is intended for men of reproductive age seeking non-hormonal contraceptive options and is currently in clinical trials to establish proof-of-concept for safety and feasibility before larger efficacy studies for regulatory approval.

Companies that use Eppin Pharma

Customer profile

Segments1 record

Ideal customer profiles1 record

Eppin Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Eppin Pharma partnerships and signals

Strategic signal

Scale indicators1 record

Eppin Pharma competitors and assessment

Company assessment

Direct peers

  • Contraline: Contraline is developing a non-hormonal, long-acting male contraceptive (ADAM hydrogel/Vasalgel). It is the most direct competitor to Eppin Pharma, sharing the non-hormonal mechanism and male contraceptive target, with a different delivery format.
  • YourChoice Therapeutics: YourChoice Therapeutics is developing a non-hormonal contraceptive for men, working on a reversible, on-demand male birth control method. It competes for the same end users and unmet need that Eppin Pharma is targeting.
  • NEXT Life Sciences: NEXT Life Sciences (formerly known as Plan A) is developing a non-hormonal, reversible male contraceptive. It pursues the same target market as Eppin Pharma — men seeking reversible contraception without hormonal intervention — making it a close direct peer.

Broad incumbents

  • Evofem Biosciences: Evofem Biosciences develops and commercializes products in women's sexual and reproductive health, including hormone-free contraceptives. Its hormone-free positioning mirrors Eppin Pharma's non-hormonal differentiation strategy in the reproductive health space.
  • Cosette Pharmaceuticals: Cosette Pharmaceuticals is a specialty pharmaceutical company with a portfolio including women's health and contraceptive products. As a broader reproductive health pharma player, it represents a comparable business model and potential commercialization partner.
  • Bayer (Pharmaceuticals Division): Bayer's pharmaceutical division has historically been a major player in contraception (e.g., Yaz, Mirena). As a global incumbent in hormonal and device-based contraception, it represents both a potential acquirer and a competitor for the male contraceptive market Eppin Pharma is targeting.
  • Merck & Co. Merck has previously invested in male contraceptive research programs and remains a global pharmaceutical incumbent. Its historical interest in male contraception makes it a relevant comparable for the broader R&D direction Eppin Pharma is pursuing.
  • Organon: Organon is a global women's health company spun out of Merck that markets multiple contraceptive products. As a broad incumbent in the reproductive health pharmaceutical space, it represents the type of large commercial player Eppin Pharma would ultimately partner with or compete against.

Emerging players

  • Population Council: The Population Council is a nonprofit research organization that has historically advanced reproductive health technologies including male contraception. While not a direct commercial peer, it operates in the same reproductive health R&D space and overlaps in male contraceptive research.
  • Dare Bioscience: Dare Bioscience is a clinical-stage biopharmaceutical company focused on women's reproductive health. While its primary focus is female contraception, it competes for the same overall reproductive health market and investor capital as Eppin Pharma.

Market position

Customer concentration

Eppin Pharma social profiles

Digital presence

Eppin Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Eppin Pharma leadership team

Management profile

Number of profiles

Eppin Pharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Eppin Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eppin Pharma

What does Eppin Pharma do?

Eppin Pharma is developing a novel non-hormonal, orally administered male contraceptive pill intended to provide reversible male birth control without hormonal intervention. The product is in early clinical development, with current activities focused on proof-of-concept studies for safety and feasibility to support future larger efficacy trials and regulatory approval.

Is Eppin Pharma a public or private company?

Eppin Pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Eppin Pharma founded?

Eppin Pharma was founded in 2001. It employs 1 to 10 people.

Where is Eppin Pharma based?

Eppin Pharma is headquartered in Durham, United States, in the North America region.

How does Eppin Pharma make money?

One revenue line is on record: pharmaceutical product revenue (future).

Who are Eppin Pharma's main competitors?

Direct peers on record are Contraline, YourChoice Therapeutics and NEXT Life Sciences. Broad incumbents are Evofem Biosciences, Cosette Pharmaceuticals, Bayer (Pharmaceuticals Division), Merck & Co. and Organon. Emerging players are Population Council and Dare Bioscience.

Does Eppin Pharma have an API?

No public API is recorded for Eppin Pharma.

What industry is Eppin Pharma in?

Eppin Pharma's product category is Reproductive Health Pharmaceuticals (Male Contraceptives). Its primary akta.pro industry code is HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Flagler Business SchoolA birth control pill for men? How a UNC scientist-turned-entrepreneur plans to curb unintended pregnancies.Eppin Pharma Inc, a UNC-Chapel Hill spinout founded in 2014 by retired professor Dr. Michael O'Rand, is developing a non-hormonal oral male contraceptive pill that blocks sperm motility by binding to a male-specific sperm surface protein. The company has received NIH SBIR and STTR grants, a $75,000 loan from the North Carolina Biotechnology Center, and up to $800,000 from the Male Contraceptive Initiative.GlobeNewswireMale Contraceptive Initiative Invests in Eppin Pharma to Support Clinical Trials for a Non-Hormonal Male ContraceptiveMale Contraceptive Initiative provided a program-related investment of up to $800,000 to Eppin Pharma to support clinical trials of a non-hormonal oral male contraceptive. The investment will establish proof-of-concept for safety and feasibility before larger efficacy studies. Eppin Pharma aims to advance its method to clinical trials in the near future.BioSpaceMale Contraceptive Initiative Invests in Eppin Pharma to Support Clinical Trials for a Non-Hormonal Male ContraceptiveThe Male Contraceptive Initiative (MCI) has partnered with Eppin Pharma to provide up to $800,000 in funding to support clinical trial activities for a novel non-hormonal oral male contraceptive. This investment aims to establish proof-of-concept for safety and feasibility as Eppin Pharma prepares for human clinical trials. The collaboration represents an expansion of MCI's portfolio to accelerate the development of reproductive autonomy options for men.